Phase 1 × OTHER × Waldenstrom Macroglobulinemia × Clear all
NCT06712810 2025-10-10

Q702 for the Treatment of Patients With Hematologic Malignancies

Mayo Clinic

Phase 1 Recruiting
46 enrolled
NCT01815749 2025-10-06

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1 Active not recruiting
30 enrolled
NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

Stanford University

Phase 1 Terminated
3 enrolled 5 charts
NCT01523223 2023-11-22

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Stanford University

Phase 1 Completed
16 enrolled
NCT01678443 2021-04-02

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Fred Hutchinson Cancer Center

Phase 1 Terminated
2 enrolled 6 charts
NCT01643603 2020-12-17

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
5 enrolled
NCT01609816 2020-03-16

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
8 enrolled
NCT01094860 2020-02-11

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
29 enrolled
NCT00036790 2019-12-17

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

University of Wisconsin, Madison

Phase 1 Completed
NCT00392691 2019-05-15

Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Swiss Cancer Institute

Phase 1 Completed
20 enrolled
NCT02168907 2018-07-02

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Wake Forest University Health Sciences

Phase 1 Terminated
1 enrolled
NCT01129193 2018-06-04

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
44 enrolled
NCT00889408 2017-12-02

DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
25 enrolled
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00004239 2016-07-04

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Alliance for Clinical Trials in Oncology

Phase 1 Terminated
10 enrolled
NCT01045928 2015-11-26

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Case Comprehensive Cancer Center

Phase 1 Terminated
5 enrolled
NCT01658319 2015-08-13

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Case Comprehensive Cancer Center

Phase 1 Completed
20 enrolled
NCT00800150 2015-06-08

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

City of Hope Medical Center

Phase 1 Terminated
6 enrolled
NCT00416923 2015-02-16

Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

University of California, San Francisco

Phase 1 Completed
10 enrolled
NCT00004258 2014-09-17

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Indiana University

Phase 1 Completed
40 enrolled
NCT00521261 2014-03-05

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1 Withdrawn
NCT00176475 2013-09-17

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Rutgers, The State University of New Jersey

Phase 1 Terminated
2 enrolled
NCT00003395 2013-06-25

Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00042900 2013-06-05

Pyroxamide in Treating Patients With Advanced Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00002750 2013-02-20

Melphalan in Patients With Neoplastic Meningitis

Duke University

Phase 1 Completed
6 enrolled
NCT00962507 2013-02-15

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

City of Hope Medical Center

Phase 1 Completed
11 enrolled
NCT00004904 2012-06-04

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Northwestern University

Phase 1 Completed